课题基金 / 基金详情

Human Milk Oligosaccharides for Prevention of Alcohol-Associated Liver Disease

Human Milk Oligosaccharides for Prevention of Alcohol-Associated Liver Disease
母乳低聚糖用于预防酒精相关性肝病
批准号:
10266673
负责人:
Derrick E Fouts
金额:
$15.78万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-22 至 2023-06-30

项目摘要

项目成果

Derrick E Fouts的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary Alcohol associated health problems are a major medical burden in industrialized countries. Alcoholic hepatitis is a distinct acute on chronic disease with significant morbidity and mortality. Patients with alcoholic hepatitis show intestinal dysbiosis and increased intestinal permeability. Recent evidence suggests that alcohol-associated liver disease is a gut dysbiosis driven disease. The mechanism of how the microbiota contributes to alcohol-associated liver disease is largely unknown. Results from our laboratory suggest that alterations in the bacterial microbiome contribute to the development of alcoholic liver disease. We observed significantly greater numbers of cytolysin-positive Enterococcus faecalis (E. faecalis) in fecal samples from patients with alcoholic hepatitis, which exacerbates alcoholic liver disease in preclinical models. How chronic alcohol use results in increased cytolysin-positive E. faecalis in the intestine is not known. This Administrative Supplement application will use Human Milk Oligosaccharides (HMOs) as dietary supplement for prevention of alcohol-associated liver disease. We hypothesize that higher numbers of intestinal E. faecalis in the intestine of patients with alcohol use disorder are facilitated by alcohol-associated changes in the glycocalyx of intestinal epithelial cells. We predict that changes in the intestinal glycocalyx can be compensated by dietary supplementation with HMOs. Through the proposed study we will characterize the role of HMOs as important resistance factor for intestinal E. faecalis colonization. Towards this goal, we will use different HMOs as dietary supplements to reduce intestinal E. faecalis and prevent ethanol-induced liver disease in mice (Specific Aim). Our studies will gain novel insights into the contributions of the intestinal microbiota to alcohol-related liver disease, and will find innovative prevention strategies for these diseases. HMOs are ideal supplements, they are safe with a precedent for FDA generally recognized as safe (GRAS) and available from multiple different supplies at large scale and low costs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Optimization, Manufacturing and Testing of a Lead Therapeutic Bacteriophage Cocktail for the Treatment of Antibiotic-Resistant Klebsiella pneumoniae Infections
  • 批准号:
    10674294
  • 项目类别:
  • 资助金额:
    $92.13万
  • 财政年份:
    2023
  • 负责人:
    Derrick E Fouts
  • 依托单位:
Combatting AntiMicrobial Resistance in Africa Using Data Science (CAMRA)
  • 批准号:
    10490849
  • 项目类别:
  • 资助金额:
    $119.88万
  • 财政年份:
    2021
  • 负责人:
    Derrick E Fouts
  • 依托单位:
CK20-004, J. Craig Venter Insitute and Cleveland VA Prevention and Intervention Epicenter
  • 批准号:
    10649550
  • 项目类别:
  • 资助金额:
    $146.16万
  • 财政年份:
    2021
  • 负责人:
    Derrick E Fouts
  • 依托单位:
CK20-004, J. Craig Venter Insitute and Cleveland VA Prevention and Intervention Epicenter
  • 批准号:
    10466704
  • 项目类别:
  • 资助金额:
    $96.72万
  • 财政年份:
    2021
  • 负责人:
    Derrick E Fouts
  • 依托单位:
海外基金